Athira Pharma, Inc. (ATHA) NASDAQ
6.75
-0.44(-6.12%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Athira Pharma, Inc.
Address
18706 North Creek Parkway
Bothell, WA 98011
United States of America (the)
Phone
425 620 8501
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
September 18, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Mark J. Litton | President, Chief Executive Officer & Director | 1.05M | 1968 |
| Kevin Church | Chief Scientific Officer | 680,085 | 1985 |
| Mark F. Worthington | General Counsel, Chief Compliance Officer & Corporate Secretary | 681,523 | 1966 |
| Robert Renninger | Chief Financial Officer | 0 | 1984 |
| Julie Rathbun | Head of Investor Relations | 0 | N/A |
| Javier San Martin | Chief Medical Officer | 0 | 1965 |
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
